Condition (MeSH)
Malignant Atrophic Papulosis
ClinicalTrials.gov lists 2 trials for Malignant Atrophic Papulosis or a narrower condition beneath it. National Heart, Lung, and Blood Institute (NHLBI) has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
2 of the 2 trials are tagged with Malignant Atrophic Papulosis itself; the rest are tagged with a narrower condition beneath it.
When did Malignant Atrophic Papulosis trials start? (2)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2023 | 1 |
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Malignant Atrophic Papulosis trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 1 |
| Phase 2 | 1 |
How many Malignant Atrophic Papulosis trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Completed | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Malignant Atrophic Papulosis trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | 2 |
Which serious adverse events do Malignant Atrophic Papulosis trials report? (4)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Anemia | 1 | 1 |
| Bacteremia | 1 | 1 |
| Sepsis | 1 | 1 |
| Worsening Sacral wound abscess | 1 | 1 |
Which publications cover Malignant Atrophic Papulosis? (1)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Cutaneous manifestations of gastrointestinal disease: part II. | Journal of the American Academy of Dermatology | 2013 | No |
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Malignant atrophic papulosis | Cases families | Worldwide | Not stated | Exact | |
| Malignant atrophic papulosis | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Exact |
| Malignant atrophic papulosis | Cases families | Worldwide | Not stated | Exact | |
| Malignant atrophic papulosis | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Exact |
| Malignant atrophic papulosis | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Unspecified |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Malignant atrophic papulosis | 679 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Malignant atrophic papulosis | 679 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.